Ketamine and Neuroinflammation: How Anti-Inflammatory Effects Support Mental Health

Depression driven by chronic inflammation often does not respond well to standard antidepressants, and researchers increasingly point to ketamine's anti-inflammatory effects as part of why low dose ketamine can help when SSRIs fail. Neuroinflammation, the activation of immune signaling inside the brain and central nervous system, is now recognized as a contributing factor in major depressive disorder, especially treatment-resistant cases. Low dose ketamine is best known for its rapid antidepressant action through NMDA receptor blockade, but it also suppresses inflammatory cytokines, calms overactive microglia, and may help protect the blood-brain barrier. Many clinics build mental health questionnaires for guided ketamine sessions into their monitoring protocols, pairing tools like the PHQ-9 or MADRS with lab-based inflammatory markers to track how a patient responds over time. This article reviews the evidence behind ketamine's anti-inflammatory mechanisms and how they connect to its effects on mood.

According to the National Institute of Mental Health, major depressive disorder is one of the most common mental health conditions in the United States, and researchers continue to investigate biological contributors such as chronic inflammation. The inflammatory hypothesis of depression, first advanced by Maes in 1995, holds that activation of the innate immune system contributes to the onset and persistence of depressive symptoms. A meta-analysis by Dowlati and colleagues (2010) covering thousands of patients found that people with major depressive disorder show consistently higher blood levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1-beta (IL-1beta) than non-depressed controls. CRP is a liver-produced marker of systemic inflammation commonly measured in routine blood work.

These peripheral inflammatory signals reach the brain through a compromised blood-brain barrier, vagal nerve signaling, and active transport at circumventricular organs, regions of the brain with a naturally permeable barrier. Once inside the central nervous system, pro-inflammatory cytokines activate microglia, the brain's resident immune cells, which then release additional inflammatory mediators. This cascade activates the enzyme indoleamine 2,3-dioxygenase (IDO), which diverts tryptophan away from serotonin production and toward the kynurenine pathway. A downstream metabolite of that pathway, quinolinic acid, acts as an NMDA receptor agonist that promotes excitotoxicity and oxidative stress in the prefrontal cortex and hippocampus. The same inflammatory state impairs brain-derived neurotrophic factor (BDNF) signaling and reduces hippocampal neurogenesis, creating conditions that favor synaptic loss and treatment resistance.

This matters clinically because patients with elevated inflammatory markers are overrepresented among those who do not respond to conventional antidepressants. Chamberlain and colleagues (2019) found that CRP levels above 3 mg/L predicted poor response to SSRIs, suggesting inflammation-driven depression may be a biologically distinct subtype that needs a different therapeutic approach. That is largely the same population for whom treatment-resistant depression becomes a clinical concern, and where ketamine is most often considered.

Ketamine is an NMDA receptor antagonist first developed as an anesthetic, and its molecular structure and pharmacological profile are documented in the PubChem compound database maintained by the National Center for Biotechnology Information. Beyond blocking NMDA receptors, ketamine directly suppresses production of pro-inflammatory cytokines. In vitro research shows that ketamine inhibits the nuclear factor kappa-B (NF-kB) signaling pathway, a master regulator of inflammatory gene expression, in macrophages, monocytes, and microglial cells (Chang et al., 2009). By blocking NF-kB from moving into the cell nucleus, ketamine reduces production of TNF-alpha, IL-6, and IL-1beta. Yang and colleagues (2013) confirmed this effect in surgical patients, showing that ketamine infusion significantly lowered circulating IL-6 compared to controls, and Kiraly and colleagues (2017) reported that psychiatric patients who responded to ketamine showed larger drops in plasma IL-6 than non-responders, a pattern consistent with anti-inflammatory action contributing to clinical improvement. A single subanesthetic infusion (0.5 mg/kg over 40 minutes) has been shown in clinical studies to reduce circulating IL-6 within four hours, with effects persisting 24 to 72 hours in some patients.

Microglia shift from a resting surveillance state to an activated, pro-inflammatory state in response to injury or chronic stress, releasing cytokines, reactive oxygen species, and quinolinic acid. Chronic microglial activation has been documented in postmortem brain tissue from people with depression and in PET imaging studies using translocator protein (TSPO) radioligands, which bind to activated microglia and make them visible on brain scans. Bhatt and colleagues (2020) showed that ketamine reduces lipopolysaccharide-induced microglial activation in rodent models, lowering TNF-alpha and nitric oxide production. Because NMDA receptors are expressed on microglia, ketamine's blockade of this receptor appears to dampen the calcium-dependent signaling that drives their inflammatory response. Ketamine also inhibits signaling through toll-like receptor 4 (TLR4), an innate immune receptor that triggers neuroinflammatory cascades on microglia and astrocytes; Wu and colleagues (2012) found that ketamine suppresses TLR4-mediated NF-kB activation and the cytokine release that follows. Separately, Chang and colleagues (2018) reported that ketamine limited lipopolysaccharide-induced blood-brain barrier breakdown in a rodent model, preserving tight junction proteins and reducing immune cell infiltration into brain tissue. For more on how ketamine interacts with the body's broader immune response, see our review of ketamine and immune function.

Ketamine's anti-inflammatory effects do not operate on their own. They intersect with its better-known glutamatergic and neurotrophic mechanisms, covered in more detail in our guide to neuroplasticity mechanisms. Because inflammation impairs BDNF signaling and promotes excitotoxicity, reducing inflammation may create more favorable conditions for the synaptic growth that underlies ketamine's rapid effects on mood. By suppressing IDO activity and slowing kynurenine pathway flux, ketamine's anti-inflammatory action may also help restore tryptophan availability for serotonin synthesis while reducing production of quinolinic acid, the neurotoxic NMDA agonist described earlier. That overlap, an anti-inflammatory drug that also lowers production of an NMDA-activating metabolite, is one reason researchers view ketamine's mechanisms as complementary rather than separate.

This convergence has practical implications for treatment planning. Patients with elevated baseline inflammatory markers, such as CRP or IL-6, may represent a subgroup particularly likely to benefit from ketamine, and serial lab testing could eventually serve as an objective marker of treatment response. Machado-Vieira and colleagues (2017) found that pre-treatment IL-6 levels predicted the size of the antidepressant response to ketamine, supporting the idea that lab-basedbiomarker-guided treatment selection is feasible. In practice, most clinics still rely primarily on validated mental health questionnaires for guided ketamine sessions, such as the PHQ-9, MADRS, or HAM-D, to track symptom change session to session, since routine inflammatory bloodwork is not yet standard of care. Combining both approaches, symptom questionnaires and inflammatory biomarkers, gives a more complete picture of how a patient is responding than either tool alone.

Ketamine's anti-inflammatory properties broaden the explanation for its antidepressant effects beyond the traditional NMDA-glutamate-BDNF framework. For clinicians, this reinforces the rationale for considering ketamine in treatment-resistant patients who show signs of inflammatory activation, including those with comorbid conditions linked to chronic inflammation, such as autoimmune disorders, metabolic syndrome, or chronic pain. Ongoing clinical trials are testing whether combining ketamine with targeted anti-inflammatory agents can extend or strengthen its antidepressant effects, and whether inflammatory biomarkers can help guide individualized dosing and scheduling. You can track this evolving evidence base in our broader research and evidence coverage. As psychiatry moves toward more individualized treatment, combining anti-inflammatory, glutamatergic, and neurotrophic perspectives, alongside practical tools like mental health questionnaires for guided ketamine sessions, will likely shape how providers select and monitor ketamine-based treatment.